Details of Disease

General Information of Disease (ID: DISD6ACL)

Disease Name Gallbladder carcinoma
Synonyms
gallbladder cancer; gallbladder carcinoma; gall bladder carcinoma; carcinoma of the gallbladder; carcinoma of gallbladder; carcinoma of gall bladder; carcinoma gallbladder; cancer of the gallbladder; cancer of gallbladder; Gall bladder carcinoma (adenocarcinoma); Gall bladder carcinoma (adeno)
Definition A carcinoma that arises from epithelial cells of the gall bladder
Disease Hierarchy
DISH9F1N: Carcinoma
DISXJUAF: Gallbladder cancer
DISFC6MM: Digestive system carcinoma
DISD6ACL: Gallbladder carcinoma
Disease Identifiers
MONDO ID
MONDO_0003220
UMLS CUI
C0235782
MedGen ID
116001
SNOMED CT ID
372140005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 2 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Gemcitabine DMSE3I7 Approved Small molecular drug [1]
Oxaliplatin DMQNWRD Approved Small molecular drug [2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 42 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ADRA2A TTWG9A4 Limited Genetic Variation [3]
ADRB3 TTMXGCW Limited Biomarker [4]
DKK2 TTST5KX Limited Genetic Variation [5]
GOT1 TTU507L Limited Genetic Variation [6]
HDGF TTKGV26 Limited Biomarker [7]
HTATIP2 TTC6IX5 Limited Altered Expression [8]
LASP1 TTZJA87 Limited Genetic Variation [9]
PRKCE TT57MT2 Limited Biomarker [10]
RNASEL TT7V0K4 Limited Genetic Variation [11]
SNCG TT5TQNZ Limited Biomarker [12]
ST8SIA4 TTDP8YM Limited Genetic Variation [13]
STOML2 TTOI329 Limited Altered Expression [14]
TXNDC12 TTL0E3Y Limited Biomarker [15]
CETP TTFQAYR Disputed Biomarker [16]
EIF5A2 TTH53G9 Disputed Altered Expression [17]
NEK7 TTJ5SWP Disputed Biomarker [18]
PBRM1 TTH8ZRL Disputed Biomarker [19]
PKLR TT31N4S Disputed Biomarker [20]
BIRC2 TTQ5LRD moderate Biomarker [21]
BIRC3 TTAIWZN moderate Biomarker [21]
CCKAR TTCG0AL moderate Altered Expression [22]
DKK3 TTY2ZV6 moderate Posttranslational Modification [23]
SPOCK1 TTF23RE moderate Biomarker [24]
TPT1 TT3PTB6 moderate Biomarker [25]
CCK TT90CMU Strong Biomarker [26]
CEACAM5 TTY6DTE Strong Biomarker [27]
CLIC1 TT8KZG6 Strong Biomarker [28]
CR1 TTEA8OW Strong Genetic Variation [29]
ERBB2 TTR5TV4 Strong Biomarker [30]
ERBB3 TTSINU2 Strong Altered Expression [31]
OGG1 TTRU01G Strong Genetic Variation [32]
OLFM4 TTK1CX7 Strong Altered Expression [33]
SERPINB5 TT1KW50 Strong Altered Expression [34]
SGCB TTEDCQ0 Strong Biomarker [35]
STMN1 TT7W5OT Strong Altered Expression [36]
STYK1 TTRMCYJ Strong Biomarker [37]
APOB TTN1IE2 Definitive Genetic Variation [38]
CLDN18 TT6PKBX Definitive Altered Expression [39]
LAPTM4B TTEJQT0 Definitive Genetic Variation [40]
PSCA TT9T4AV Definitive Altered Expression [41]
RALBP1 TTVSRUA Definitive Biomarker [42]
RIPK1 TTVJHX8 Definitive Biomarker [42]
------------------------------------------------------------------------------------
⏷ Show the Full List of 42 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC25A22 DTJCWP8 Strong Altered Expression [43]
------------------------------------------------------------------------------------
This Disease Is Related to 5 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
HSD17B7 DEDMWFX Limited Altered Expression [44]
CYP39A1 DEEG96X Disputed Biomarker [16]
CYP7B1 DE36TMY Disputed Biomarker [16]
SULT2B1 DEZBN53 Disputed Altered Expression [16]
CYP7A1 DEDZRQ1 Strong Genetic Variation [45]
------------------------------------------------------------------------------------
This Disease Is Related to 83 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
CARTPT OTTE4V9S Limited Genetic Variation [46]
CCL28 OTY6XNQ7 Limited Biomarker [47]
CDC6 OTX93FE7 Limited Altered Expression [48]
CHD5 OTS5EVHH Limited Altered Expression [49]
CIB2 OT9ZJX1I Limited Biomarker [50]
CIZ1 OT3UKHPI Limited Biomarker [51]
CPEB4 OTW1SCZW Limited Biomarker [52]
DEPP1 OTB36PHJ Limited Genetic Variation [53]
E2F7 OTWW358N Limited Biomarker [54]
EIF3D OTDOMP80 Limited Biomarker [55]
EMP3 OTODMJ1D Limited Altered Expression [56]
FKTN OTQ9GCXL Limited Biomarker [57]
FLNC OT3F8J6Y Limited Biomarker [58]
FOXL1 OT89XFPN Limited Altered Expression [59]
GALNT3 OT7M67WT Limited Altered Expression [60]
GCNT2 OTRUIMC4 Limited Genetic Variation [6]
GDF9 OTNTVKVU Limited Altered Expression [48]
GNL3 OTILGYO4 Limited Altered Expression [61]
GOPC OTRBGH71 Limited Genetic Variation [53]
GPC1 OTQKRSSV Limited Altered Expression [62]
GSTM3 OTLA2WJT Limited Biomarker [63]
HIPK3 OT4WYQM2 Limited Biomarker [64]
HLTF OTRX2OSF Limited Biomarker [58]
IGF2BP2 OT4ZSEEE Limited Biomarker [65]
IMMP2L OT9WGAFD Limited Biomarker [65]
KLHL1 OTAX6SAD Limited Altered Expression [66]
MACC1 OTV3DLX0 Limited Biomarker [67]
MAP2K4 OTZPZX11 Limited Biomarker [68]
MMP19 OTLSTT2B Limited Altered Expression [69]
MPG OTAHW80B Limited Biomarker [70]
MYBL2 OTZ3JX8Q Limited Biomarker [71]
NEDD4L OT1B19RU Limited Altered Expression [72]
NLK OT2LETFS Limited Biomarker [73]
PCBP1 OTHN0TD7 Limited Biomarker [74]
PHLPP1 OTIFXW8D Limited Altered Expression [75]
PLAC8 OT3SYRUJ Limited Biomarker [76]
PPP1R10 OT7GE3BN Limited Altered Expression [77]
PSAP OTUOEKY7 Limited Biomarker [78]
RNF125 OTBD1Q3X Limited Altered Expression [79]
SCAMP1 OTFS4IKJ Limited Biomarker [80]
SEMA3B OTCZCPMS Limited Posttranslational Modification [81]
SKAP2 OTSF44KP Limited Altered Expression [44]
SPPL3 OT2HLJF6 Limited Biomarker [65]
SYCE1L OTXU44F3 Limited Altered Expression [66]
SYTL2 OTUIOWKL Limited Altered Expression [14]
TCF12 OTZVONNU Limited Biomarker [82]
TMPRSS4 OTCCGY2K Limited Altered Expression [83]
TP53BP2 OTOWJ2Y4 Limited Altered Expression [84]
TPD52 OTPKSK43 Limited Biomarker [85]
TPTE2 OTR3K733 Limited Biomarker [86]
TRIM31 OT7VW6RP Limited Biomarker [87]
TRO OTRZQMU8 Limited Altered Expression [88]
CREBRF OT2GK1HI Disputed Altered Expression [89]
ELP5 OTW5R7YD Disputed Biomarker [90]
MBD1 OTD19VO6 Disputed Altered Expression [26]
NSUN2 OTZCNM33 Disputed Altered Expression [91]
PA2G4 OT7IG7HT Disputed Biomarker [92]
PLEK2 OTUBWUUK Disputed Biomarker [93]
RPL6 OTRU71O4 Disputed Biomarker [91]
RRN3 OTKGOZ49 Disputed Altered Expression [92]
TENM3 OTWY13GR Disputed Biomarker [94]
TENM4 OT91K3FC Disputed Genetic Variation [94]
KRR1 OTCMJ3K3 moderate Biomarker [42]
SEMA6A OTDQ7QAW moderate Biomarker [95]
ABI3BP OTW8DN50 Strong Altered Expression [96]
ATP5F1B OTLFZUQK Strong Biomarker [97]
CDO1 OTLG1P77 Strong Biomarker [98]
DCC OT2C1SHW Strong Biomarker [99]
DMBT1 OTVNU9D9 Strong Biomarker [100]
EIF6 OTEXMUED Strong Biomarker [101]
PPIG OTZ8BTTM Strong Biomarker [102]
SFN OTLJCZ1U Strong Altered Expression [103]
SSBP2 OTYG1G80 Strong Posttranslational Modification [104]
STOM OTC8R6EH Strong Altered Expression [14]
TBC1D9 OTSSCTB5 Strong Biomarker [76]
ABCG8 OTIJ76XW Definitive Genetic Variation [105]
AKT1S1 OT4JHN4Y Definitive Biomarker [106]
CROCC OTVNOZSM Definitive Altered Expression [107]
KPNA2 OTU7FOE6 Definitive Altered Expression [108]
MPZL1 OTJSUUHR Definitive Altered Expression [109]
MUC5B OTPW6K5C Definitive Biomarker [39]
NONO OTN36Q6U Definitive Biomarker [110]
TFDP1 OT6RZ7VT Definitive Biomarker [111]
------------------------------------------------------------------------------------
⏷ Show the Full List of 83 DOT(s)

References

1 Gemcitabine FDA Label
2 Oxaliplatin FDA Label
3 Association of adrenergic receptor gene polymorphisms in gallbladder cancer susceptibility in a North Indian population.J Cancer Res Clin Oncol. 2014 May;140(5):725-35. doi: 10.1007/s00432-014-1621-7. Epub 2014 Feb 21.
4 A Multiple Interaction Analysis Reveals ADRB3 as a Potential Candidate for Gallbladder Cancer Predisposition via a Complex Interaction with Other Candidate Gene Variations.Int J Mol Sci. 2015 Nov 25;16(12):28038-49. doi: 10.3390/ijms161226077.
5 Association of Wnt signaling pathway genetic variants in gallbladder cancer susceptibility and survival.Tumour Biol. 2016 Jun;37(6):8083-95. doi: 10.1007/s13277-015-4728-9. Epub 2015 Dec 29.
6 Association of genetic variants of cancer stem cell gene CD44 haplotypes with gallbladder cancer susceptibility in North Indian population.Tumour Biol. 2014 Mar;35(3):2583-9. doi: 10.1007/s13277-013-1340-8. Epub 2013 Nov 5.
7 Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion.Med Oncol. 2013;30(2):587. doi: 10.1007/s12032-013-0587-7. Epub 2013 Apr 23.
8 MCM2 and TIP30 are prognostic markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of the gallbladder.Mol Med Rep. 2016 Nov;14(5):4581-4592. doi: 10.3892/mmr.2016.5851. Epub 2016 Oct 13.
9 LASP-1 induces proliferation, metastasis and cell cycle arrest at the G2/M phase in gallbladder cancer by down-regulating S100P via the PI3K/AKT pathway.Cancer Lett. 2016 Mar 28;372(2):239-50. doi: 10.1016/j.canlet.2016.01.008. Epub 2016 Jan 18.
10 miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer.Cell Death Dis. 2017 May 11;8(5):e2770. doi: 10.1038/cddis.2017.178.
11 Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China.Cancer Res. 2008 Aug 1;68(15):6442-52. doi: 10.1158/0008-5472.CAN-08-0444.
12 SNCG gene silencing in gallbladder cancer cells inhibits key tumorigenic activities.Front Biosci (Landmark Ed). 2012 Jan 1;17(4):1589-98. doi: 10.2741/4005.
13 Cholecystokinin receptor A gene polymorphism in gallstone disease and gallbladder cancer.J Gastroenterol Hepatol. 2008 Jun;23(6):970-5. doi: 10.1111/j.1440-1746.2007.05170.x. Epub 2007 Oct 11.
14 Enhanced SLP-2 promotes invasion and metastasis by regulating Wnt/-catenin signal pathway in colorectal cancer and predicts poor prognosis.Pathol Res Pract. 2019 Jan;215(1):57-67. doi: 10.1016/j.prp.2018.10.018. Epub 2018 Oct 24.
15 Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene.Int J Cancer. 1995 Apr 10;61(2):206-13. doi: 10.1002/ijc.2910610211.
16 Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response.Cell Cycle. 2019 Dec;18(23):3337-3350. doi: 10.1080/15384101.2019.1676581. Epub 2019 Oct 10.
17 Overexpression of EIF5A2 is associated with poor survival and aggressive tumor biology in gallbladder cancer.Histol Histopathol. 2020 Jun;35(6):579-587. doi: 10.14670/HH-18-186. Epub 2019 Nov 20.
18 Downregulation of NIMA-related kinase-7 inhibits cell proliferation by inducing cell cycle arrest in human retinoblastoma cells.Exp Ther Med. 2018 Feb;15(2):1360-1366. doi: 10.3892/etm.2017.5558. Epub 2017 Nov 23.
19 Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?.HPB (Oxford). 2019 Dec;21(12):1648-1655. doi: 10.1016/j.hpb.2019.04.002. Epub 2019 May 20.
20 Circular RNA FOXP1 promotes tumor progression and Warburg effect in gallbladder cancer by regulating PKLR expression.Mol Cancer. 2019 Oct 17;18(1):145. doi: 10.1186/s12943-019-1078-z.
21 cIAP1 promotes proliferation and migration and prevents apoptosis in gallbladder cancer in vitro.Biosci Rep. 2019 Apr 12;39(4):BSR20182266. doi: 10.1042/BSR20182266. Print 2019 Apr 30.
22 Differential expression of cholecystokinin A receptor in gallbladder cancer in the young and elderly suggests two subsets of the same disease?.Biomed Res Int. 2014;2014:625695. doi: 10.1155/2014/625695. Epub 2014 Jun 15.
23 Dickkopf Homolog 3 (DKK3) Acts as a Potential Tumor Suppressor in Gallbladder Cancer.Front Oncol. 2019 Oct 29;9:1121. doi: 10.3389/fonc.2019.01121. eCollection 2019.
24 Identification of messenger and long noncoding RNAs associated with gallbladder cancer via gene expression profile analysis.J Cell Biochem. 2019 Dec;120(12):19377-19387. doi: 10.1002/jcb.28953. Epub 2019 Sep 9.
25 Correction to: Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer.J Exp Clin Cancer Res. 2019 Sep 3;38(1):385. doi: 10.1186/s13046-019-1378-6.
26 MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine.Cancer Cell Int. 2019 Sep 9;19:232. doi: 10.1186/s12935-019-0948-1. eCollection 2019.
27 Scoring System to Predict pt2 in Gallbladder Cancer Based on Carcinoembryonic Antigen and Tumor Diameter.Scand J Surg. 2020 Dec;109(4):301-308. doi: 10.1177/1457496919866016. Epub 2019 Jul 29.
28 Effect of CLIC1 gene silencing on proliferation, migration, invasion and apoptosis of human gallbladder cancer cells.J Cell Mol Med. 2018 May;22(5):2569-2579. doi: 10.1111/jcmm.13499. Epub 2018 Mar 8.
29 Complement receptor 1 (A3650G RsaI and intron 27 HindIII) polymorphisms and risk of gallbladder cancer in north Indian population.Scand J Immunol. 2009 Dec;70(6):614-20. doi: 10.1111/j.1365-3083.2009.02329.x.
30 Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo.Biomed Res Int. 2019 Mar 25;2019:9205851. doi: 10.1155/2019/9205851. eCollection 2019.
31 Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.Gut. 2019 Jun;68(6):1024-1033. doi: 10.1136/gutjnl-2018-316039. Epub 2018 Jun 28.
32 Gallbladder cancer predisposition: a multigenic approach to DNA-repair, apoptotic and inflammatory pathway genes.PLoS One. 2011 Jan 21;6(1):e16449. doi: 10.1371/journal.pone.0016449.
33 Olfactomedin-4 in digestive diseases: A mini-review.World J Gastroenterol. 2018 May 7;24(17):1881-1887. doi: 10.3748/wjg.v24.i17.1881.
34 Significance of methylation status of MASPIN gene and its protein expression in prognosis of gallbladder cancer.Asia Pac J Clin Oncol. 2019 Oct;15(5):e120-e125. doi: 10.1111/ajco.13129. Epub 2019 Feb 10.
35 MiR-335 promotes cell proliferation by inhibiting MEF2D and sensitizes cells to 5-Fu treatment in gallbladder carcinoma.Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9829-9839. doi: 10.26355/eurrev_201911_19546.
36 Stathmin decreases cholangiocarcinoma cell line sensitivity to staurosporine-triggered apoptosis via the induction of ERK and Akt signaling.Oncotarget. 2017 Feb 28;8(9):15775-15788. doi: 10.18632/oncotarget.15005.
37 STYK1 promotes cancer cell proliferation and malignant transformation by activating PI3K-AKT pathway in gallbladder carcinoma. Int J Biochem Cell Biol. 2018 Apr;97:16-27.
38 Roles of ApoB-100 gene polymorphisms and the risks of gallstones and gallbladder cancer: a meta-analysis.PLoS One. 2013 Apr 18;8(4):e61456. doi: 10.1371/journal.pone.0061456. Print 2013.
39 Mucin 5B, carbonic anhydrase 9 and claudin 18 are potential theranostic markers of gallbladder carcinoma.Histopathology. 2019 Mar;74(4):597-607. doi: 10.1111/his.13797. Epub 2019 Jan 28.
40 Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients.Med Oncol. 2012 Dec;29(4):2809-13. doi: 10.1007/s12032-012-0173-4.
41 Down-regulation of Immune-related Genes by PSCA in Gallbladder Cancer Cells Implanted into Mice.Anticancer Res. 2015 May;35(5):2619-25.
42 Receptorinteracting serine/threonineprotein kinase 1 promotes the progress and lymph metastasis of gallbladder cancer.Oncol Rep. 2019 Dec;42(6):2435-2449. doi: 10.3892/or.2019.7331. Epub 2019 Sep 23.
43 SLC25A22 promotes proliferation and metastasis by activating MAPK/ERK pathway in gallbladder cancer.Cancer Cell Int. 2019 Feb 14;19:33. doi: 10.1186/s12935-019-0746-9. eCollection 2019.
44 UHRF1 depletion suppresses growth of gallbladder cancer cells through induction of apoptosis and cell cycle arrest.Oncol Rep. 2014 Jun;31(6):2635-43. doi: 10.3892/or.2014.3145. Epub 2014 Apr 23.
45 CYP7A1 (-204 A>C; rs3808607 and -469 T>C; rs3824260) promoter polymorphisms and risk of gallbladder cancer in North Indian population.Metabolism. 2010 Jun;59(6):767-73. doi: 10.1016/j.metabol.2009.09.021. Epub 2009 Dec 16.
46 Significant role of estrogen and progesterone receptor sequence variants in gallbladder cancer predisposition: a multi-analytical strategy.PLoS One. 2012;7(7):e40162. doi: 10.1371/journal.pone.0040162. Epub 2012 Jul 10.
47 CCK1 receptor is involved in the regulation of protein lysine acetylation in GBC-SD cells and gallbladder carcinoma.Ir J Med Sci. 2017 Nov;186(4):883-888. doi: 10.1007/s11845-017-1603-2. Epub 2017 May 3.
48 Expression of CDC6 and GDF-9 and their clinicopathological significances in benign and malignant lesions of the gallbladder.Cancer Biomark. 2012;11(2-3):107-14. doi: 10.3233/CBM-2012-0267.
49 Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma.Clin Transl Oncol. 2013 Mar;15(3):198-204. doi: 10.1007/s12094-012-0903-2. Epub 2012 Jul 24.
50 Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer.Anticancer Res. 2007 May-Jun;27(3B):1679-84.
51 CIZ1 promoted the growth and migration of gallbladder cancer cells.Tumour Biol. 2015 Apr;36(4):2583-91. doi: 10.1007/s13277-014-2876-y. Epub 2014 Nov 28.
52 MicroRNA-29c-5p suppresses gallbladder carcinoma progression by directly targeting CPEB4 and inhibiting the MAPK pathway.Cell Death Differ. 2017 Mar;24(3):445-457. doi: 10.1038/cdd.2016.146. Epub 2017 Jan 6.
53 Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR.Genes Chromosomes Cancer. 2014 Dec;53(12):1033-40. doi: 10.1002/gcc.22212. Epub 2014 Sep 18.
54 MicroRNA-30a-5p inhibits gallbladder cancer cell proliferation, migration and metastasis by targeting E2F7.Cell Death Dis. 2018 Mar 14;9(3):410. doi: 10.1038/s41419-018-0444-x.
55 EIF3D promotes gallbladder cancer development by stabilizing GRK2 kinase and activating PI3K-AKT signaling pathway.Cell Death Dis. 2017 Jun 8;8(6):e2868. doi: 10.1038/cddis.2017.263.
56 RETRACTED: EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway.Cancer Lett. 2018 Aug 28;430:97-108. doi: 10.1016/j.canlet.2018.05.022. Epub 2018 May 17.
57 Sequential occurrence of preneoplastic lesions and accumulation of loss of heterozygosity in patients with gallbladder stones suggest causal association with gallbladder cancer.Ann Surg. 2014 Dec;260(6):1073-80. doi: 10.1097/SLA.0000000000000495.
58 Epigenetic profiling of gallbladder cancer and gall stone diseases: Evaluation of role of tumour associated genes.Gene. 2016 Feb 1;576(2 Pt 2):743-52. doi: 10.1016/j.gene.2015.10.004. Epub 2015 Oct 8.
59 Forkhead box L1 is frequently downregulated in gallbladder cancer and inhibits cell growth through apoptosis induction by mitochondrial dysfunction.PLoS One. 2014 Jul 10;9(7):e102084. doi: 10.1371/journal.pone.0102084. eCollection 2014.
60 Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder.Clin Cancer Res. 2004 Mar 15;10(6):2090-9. doi: 10.1158/1078-0432.ccr-1024-03.
61 Significance of epithelial growth factor in the epithelial-mesenchymal transition of human gallbladder cancer cells.Cancer Sci. 2012 Jun;103(6):1165-71. doi: 10.1111/j.1349-7006.2012.02264.x. Epub 2012 Apr 3.
62 High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.Cancer Med. 2018 Nov;7(11):5525-5533. doi: 10.1002/cam4.1833. Epub 2018 Oct 24.
63 Genetic polymorphisms in GSTM1, GSTT1, GSTP1, GSTM3 and the susceptibility to gallbladder cancer in North India.Biomarkers. 2006 May-Jun;11(3):250-61. doi: 10.1080/13547500600648697.
64 Circular RNA HIPK3 promotes gallbladder cancer cell growth by sponging microRNA-124.Biochem Biophys Res Commun. 2018 Sep 5;503(2):863-869. doi: 10.1016/j.bbrc.2018.06.088. Epub 2018 Aug 2.
65 IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer.Oncotarget. 2017 Sep 21;8(52):89736-89745. doi: 10.18632/oncotarget.21116. eCollection 2017 Oct 27.
66 Expression of multidrug resistance-associated protein 2 in human gallbladder carcinoma.Biomed Res Int. 2013;2013:527534. doi: 10.1155/2013/527534. Epub 2013 Jun 16.
67 Downregulated expression of metastasis associated in colon cancer 1 (MACC1) reduces gallbladder cancer cell proliferation and invasion.Tumour Biol. 2014 Apr;35(4):3771-8. doi: 10.1007/s13277-013-1499-z. Epub 2014 Jan 15.
68 Overexpressed microRNA-136 works as a cancer suppressor in gallbladder cancer through suppression of JNK signaling pathway via inhibition of MAP2K4.Am J Physiol Gastrointest Liver Physiol. 2019 Nov 1;317(5):G670-G681. doi: 10.1152/ajpgi.00055.2019. Epub 2019 Aug 1.
69 Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression.J Hepatol. 2015 Dec;63(6):1429-39. doi: 10.1016/j.jhep.2015.08.007. Epub 2015 Aug 17.
70 Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.Oncotarget. 2017 Apr 18;8(16):26169-26184. doi: 10.18632/oncotarget.15410.
71 MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer.Cell Physiol Biochem. 2017;41(5):2117-2131. doi: 10.1159/000475454. Epub 2017 Apr 17.
72 Nedd4L modulates the transcription of metalloproteinase-1 and -13 genes to increase the invasive activity of gallbladder cancer.Int J Exp Pathol. 2011 Apr;92(2):79-86. doi: 10.1111/j.1365-2613.2010.00740.x. Epub 2010 Oct 5.
73 NLK is a key regulator of proliferation and migration in gallbladder carcinoma cells.Mol Cell Biochem. 2012 Oct;369(1-2):27-33. doi: 10.1007/s11010-012-1365-0. Epub 2012 Jun 24.
74 PCBP1 is an important mediator of TGF--induced epithelial to mesenchymal transition in gall bladder cancer cell line GBC-SD.Mol Biol Rep. 2014 Aug;41(8):5519-24. doi: 10.1007/s11033-014-3428-7. Epub 2014 Jun 3.
75 SNORA74B gene silencing inhibits gallbladder cancer cells by inducing PHLPP and suppressing Akt/mTOR signaling.Oncotarget. 2017 Mar 21;8(12):19980-19996. doi: 10.18632/oncotarget.15301.
76 PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma.Biochem Biophys Res Commun. 2019 Aug 27;516(3):983-990. doi: 10.1016/j.bbrc.2019.06.121. Epub 2019 Jul 2.
77 miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells.Tumour Biol. 2014 Feb;35(2):1503-10. doi: 10.1007/s13277-013-1207-z.
78 Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics.Biochem Biophys Res Commun. 2014 Apr 18;446(4):863-9. doi: 10.1016/j.bbrc.2014.03.017. Epub 2014 Mar 20.
79 Ring finger protein 125, as a potential highly aggressive and unfavorable prognostic biomarker, promotes the invasion and metastasis of human gallbladder cancers via activating the TGF- 1-SMAD3-ID1 signaling pathway.Oncotarget. 2017 Jul 25;8(30):49897-49914. doi: 10.18632/oncotarget.18180.
80 Inhibition of SCAMP1 suppresses cell migration and invasion in human pancreatic and gallbladder cancer cells.Tumour Biol. 2013 Oct;34(5):2731-9. doi: 10.1007/s13277-013-0825-9. Epub 2013 May 8.
81 Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma.Cancer Lett. 2007 May 18;250(1):100-6. doi: 10.1016/j.canlet.2006.09.019. Epub 2006 Nov 7.
82 HDAC1 promoted migration and invasion binding with TCF12 by promoting EMT progress in gallbladder cancer.Oncotarget. 2016 May 31;7(22):32754-64. doi: 10.18632/oncotarget.8740.
83 Clinical implication of TMPRSS4 expression in human gallbladder cancer.Tumour Biol. 2014 Jun;35(6):5481-6. doi: 10.1007/s13277-014-1716-4. Epub 2014 Feb 15.
84 Downregulation of ASPP2 promotes gallbladder cancer metastasis and macrophage recruitment via aPKC-/GLI1 pathway.Cell Death Dis. 2018 Nov 2;9(11):1115. doi: 10.1038/s41419-018-1145-1.
85 Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease.Tumour Biol. 2016 Nov;37(11):14687-14699. doi: 10.1007/s13277-016-5355-9. Epub 2016 Sep 14.
86 Downregulation of TPTE2P1 Inhibits Migration and Invasion of Gallbladder Cancer Cells.Chem Biol Drug Des. 2015 Oct;86(4):656-62. doi: 10.1111/cbdd.12533. Epub 2015 May 11.
87 Knockdown of TRIM31 suppresses proliferation and invasion of gallbladder cancer cells by down-regulating MMP2/9 through the PI3K/Akt signaling pathway.Biomed Pharmacother. 2018 Jul;103:1272-1278. doi: 10.1016/j.biopha.2018.04.120. Epub 2018 May 7.
88 Enhanced expression of trophinin promotes invasive and metastatic potential of human gallbladder cancer cells.J Cancer Res Clin Oncol. 2009 Apr;135(4):581-90. doi: 10.1007/s00432-008-0492-1. Epub 2008 Oct 10.
89 MicroRNA-181b blocks gensenoside Rg3-mediated tumor suppression of gallbladder carcinoma by promoting autophagy flux via CREBRF/CREB3 pathway.Am J Transl Res. 2019 Sep 15;11(9):5776-5787. eCollection 2019.
90 Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer.Nat Commun. 2019 Dec 2;10(1):5492. doi: 10.1038/s41467-019-13420-x.
91 NOP2/Sun RNA methyltransferase 2 promotes tumor progression via its interacting partner RPL6 in gallbladder carcinoma.Cancer Sci. 2019 Nov;110(11):3510-3519. doi: 10.1111/cas.14190. Epub 2019 Sep 23.
92 Circular RNA circERBB2 promotes gallbladder cancer progression by regulating PA2G4-dependent rDNA transcription.Mol Cancer. 2019 Nov 21;18(1):166. doi: 10.1186/s12943-019-1098-8.
93 PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway.J Exp Clin Cancer Res. 2019 Jun 10;38(1):247. doi: 10.1186/s13046-019-1250-8.
94 Laparoscopy versus laparotomy approach of a radical resection for gallbladder cancer: a retrospective comparative study.Surg Endosc. 2020 Jul;34(7):2926-2938. doi: 10.1007/s00464-019-07075-4. Epub 2019 Aug 28.
95 -Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic response to gemcitabine in gallbladder carcinoma cells via targeting the AMPK/SREBP1 cascades.J Cell Mol Med. 2020 Jan;24(1):760-771. doi: 10.1111/jcmm.14785. Epub 2019 Nov 25.
96 Long noncoding RNA MALAT1 potentiates growth and inhibits senescence by antagonizing ABI3BP in gallbladder cancer cells.J Exp Clin Cancer Res. 2019 Jun 7;38(1):244. doi: 10.1186/s13046-019-1237-5.
97 ATP5b and 2-microglobulin are predictive markers for the prognosis of patients with gallbladder cancer.J Mol Histol. 2015 Feb;46(1):57-65. doi: 10.1007/s10735-014-9597-9. Epub 2014 Oct 14.
98 Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.PLoS One. 2017 Nov 21;12(11):e0188178. doi: 10.1371/journal.pone.0188178. eCollection 2017.
99 Comparison of short- and long-term outcomes between anatomical subtypes of resected biliary tract cancer in a Western high-volume center.HPB (Oxford). 2020 Mar;22(3):405-414. doi: 10.1016/j.hpb.2019.07.011. Epub 2019 Sep 4.
100 DMBT1 suppresses progression of gallbladder carcinoma through PI3K/AKT signaling pathway by targeting PTEN.Biosci Biotechnol Biochem. 2019 Dec;83(12):2257-2264. doi: 10.1080/09168451.2019.1654361. Epub 2019 Aug 14.
101 Eukaryotic translation initiation factor 6 overexpression plays a major role in the translational control of gallbladder cancer.J Cancer Res Clin Oncol. 2019 Nov;145(11):2699-2711. doi: 10.1007/s00432-019-03030-x. Epub 2019 Oct 4.
102 A multigenic approach to evaluate genetic variants of PLCE1, LXRs, MMPs, TIMP, and CYP genes in gallbladder cancer predisposition.Tumour Biol. 2014 Sep;35(9):8597-606. doi: 10.1007/s13277-014-2094-7. Epub 2014 May 27.
103 Role of stratifin (14-3-3 sigma) in adenocarcinoma of gallbladder: A novel prognostic biomarker.Surg Oncol. 2020 Mar;32:57-62. doi: 10.1016/j.suronc.2019.10.022. Epub 2019 Nov 2.
104 Single-stranded DNA binding protein 2 expression is associated with patient survival in hepatocellular carcinoma.BMC Cancer. 2018 Dec 12;18(1):1244. doi: 10.1186/s12885-018-5158-z.
105 Variants in ABCG8 and TRAF3 genes confer risk for gallstone disease in admixed Latinos with Mapuche Native American ancestry.Sci Rep. 2019 Jan 28;9(1):772. doi: 10.1038/s41598-018-35852-z.
106 PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40kDa (PRAS40).J Cell Commun Signal. 2019 Jun;13(2):163-177. doi: 10.1007/s12079-018-00503-5. Epub 2019 Jan 21.
107 Up-regulated microRNA-33b inhibits epithelial-mesenchymal transition in gallbladder cancer through down-regulating CROCC.Biosci Rep. 2020 Jan 31;40(1):BSR20190108. doi: 10.1042/BSR20190108.
108 E2F1 and E2F7 differentially regulate KPNA2 to promote the development of gallbladder cancer.Oncogene. 2019 Feb;38(8):1269-1281. doi: 10.1038/s41388-018-0494-7. Epub 2018 Sep 25.
109 MPZL1 is highly expressed in advanced gallbladder carcinoma and promotes the aggressive behavior of human gallbladder carcinoma GBCSD cells.Mol Med Rep. 2019 Sep;20(3):2725-2733. doi: 10.3892/mmr.2019.10506. Epub 2019 Jul 18.
110 Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma.Biochem Biophys Res Commun. 2020 Feb 19;522(4):952-959. doi: 10.1016/j.bbrc.2019.10.104. Epub 2019 Dec 4.
111 Long non-coding RNA DILC promotes the progression of gallbladder carcinoma.Gene. 2019 Apr 30;694:102-110. doi: 10.1016/j.gene.2018.12.086. Epub 2019 Feb 1.